The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia

B-cell receptor (BCR) associated kinases including spleen tyrosine kinase (SYK) contribute to the pathogenesis of B-cell malignancies. SYK is persistently phosphorylated in a subset of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), and SYK inhibition results in abrogation of down...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Spurgeon, Stephen E., Coffey, Greg, Fletcher, Luke B., Burke, Russell, Tyner, Jeffrey W., Druker, Brian J., Betz, Andreas, DeGuzman, Francis, Pak, Yvonne, Baker, Dale, Pandey, Anjali, Hollenbach, Stanley J., Sinha, Uma, Loriaux, Marc M.
Format: Artigo
Langue:Inglês
Publié: The American Society for Pharmacology and Experimental Therapeutics 2013
Sujets:
Chemotherapy, Antibiotics, and Gene Therapy
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3558816/
https://ncbi.nlm.nih.gov/pubmed/23220742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.112.200832
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires